Berkeley Ecosystems

Berkeley Ecosystems Website Coming Soon

The Berkeley Ecosystems, hosted by the College of Chemistry, provides ongoing opportunities for you to learn, explore, and connect with fellow faculty, alumni, students, and industry innovators in content-specific areas. As part of our Ecosystems, we will be offering a series of panel discussions, talks, and conversations. We will also promote opportunities to connect with and recruit Berkeley students.

The Berkeley Ecosystems website is coming soon! Please check this page again for info.

Upcoming Event

Don't miss our first Ecosystem Event "The Future of Biotechnology" featuring:

Maria Fardis

Dr. Maria Fardis

Dr. Maria Fardis joined Iovance Biotherapeutics as President and Chief Executive Officer and was appointed to the Board of Directors in 2016. She has led the transformation of Iovance from early-stage development to a late-stage company with multiple pivotal programs for T-cell based therapies for solid tumors. Dr. Fardis received her Ph.D. in Organic Chemistry from the University of California, Berkeley and her B.S. summa cum laude, in Chemistry from the University of Illinois, Urbana-Champaign. Dr. Fardis holds an M.B.A., with highest honors, from Golden Gate University.

David Rabuka

Dr. David Rabuka

Dr. David Rabuka is the founder and CEO of Acrigen Biosciences, a company developing safe and efficient methods for gene editing therapy. David received a Ph.D. in Chemistry at the University of California, Berkeley as a Chevron Fellow in the lab of Professor Carolyn Bertozzi where his research included developing and applying protein bioconjugation technology to cell surface modification. Prior to pursuing his Ph.D., David worked at the Burnham Institute synthesizing complex glycans and later at Optimer Pharmaceuticals, which he joined as an early employee, focused on the development of glycan and macrolide based antibiotics.

David Schaffer

Dr. David Schaffer

Dr. David Schaffer is a Professor of Chemical and Biomolecular Engineering, Bioengineering, and Neuroscience at University of California, Berkeley, where he also serves as the Director of the Berkeley Stem Cell Center. At Berkeley, Dr. Schaffer applies engineering principles to enhance stem cell and gene therapy approaches for neuroregeneration. This work includes mechanistic investigation of stem cell control, as well as molecular evolution and engineering of viral gene delivery vehicles. He graduated from Stanford University with a B.S. degree in Chemical Engineering in 1993. Afterward, he attended Massachusetts Institute of Technology and earned his Ph.D. also in Chemical Engineering in 1998 with Professor Doug Lauffenburger, while minoring in Molecular and Cell Biology. Finally, he conducted a postdoctoral fellowship in the laboratory of Fred Gage at the Salk Institute for Biological Studies in La Jolla, CA, before moving to UC Berkeley in 1999.

Steve Worland

Dr. Steve Worland

Dr. Steve Worland is President, Chief Executive Officer and a Director of eFFECTOR Therapeutics, which he co-founded in 2012. eFFECTOR is a clinical stage biotherapeutics company developing selective translation regulators for cancer and other serious diseases, based on technology originally developed at UCSF. Dr. Worland is also a Board member of Tracon Pharmaceuticals (NASDAQ:TCON) and privately held Forge Therapeutics. Dr. Worland was an NIH postdoctoral fellow in Molecular Biology at Harvard University and completed his Ph.D. in Chemistry at the University of California, Berkeley. He received his B.S. with highest honors in Biological Chemistry from the University of Michigan.